Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
about
Androgen deprivation therapy for prostate cancer-review of indications in 20105alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.Update on the use of dutasteride in the management of benign prostatic hypertrophy.The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression.American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB.Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study.Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors.Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy.
P2860
Q34111603-6F626174-E507-41E0-BA84-79ECFBE4A6DBQ34887797-EFEA40B7-5084-4A14-91F3-0E891088B6DBQ37017292-1BD8DB99-9FB5-4CDF-BACC-814662A83448Q37086672-A93B36FC-A900-42F4-9FED-2DF7F0406341Q37230480-35B464AC-2DE3-433D-A3FD-6E8100B33799Q37424419-8E6E474F-39D9-49D3-8D4C-BC7FBD7B4BA2Q39006967-4A2A0B6E-4612-4FF2-A4BE-312ACC2E1E2DQ41192354-3983E39A-E927-410A-944B-63462083A09CQ47700776-D4787FAE-F511-43A6-9ED0-939B2613D09DQ48147954-1A5F9461-3E2F-41EE-A696-9CBDCB395A02Q48553280-E4C10BF4-659E-4CFC-B385-531C13F6B1A4
P2860
Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@ast
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@en
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@nl
type
label
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@ast
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@en
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@nl
prefLabel
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@ast
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@en
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@nl
P2093
P1433
P1476
Efficacy of neoadjuvant bicalu ...... before prostate brachytherapy.
@en
P2093
Brian Kurko
Gregory S Merrick
Kent E Wallner
Robert W Galbreath
Wayne M Butler
Zachariah A Allen
P304
P356
10.1016/J.UROLOGY.2006.01.061
P407
P577
2006-07-01T00:00:00Z